10 YEARS OF SUPPORTING FAMILIES, RESEARCH, AND COMMUNITIES
UNITY. HOPE. STRENGTH. LOVE
10 YEARS OF SUPPORTING FAMILIES, RESEARCH, AND COMMUNITIES
UNITY. HOPE. STRENGTH. LOVE
What is KCNQ2?
KCNQ2 is a gene that plays a vital role in brain function by controlling how nerve cells communicate through electrical signals. It is essential for normal brain activity, particularly in early development. Changes in the KCNQ2 gene are among the most common genetic causes of neonatal seizures, but KCNQ2-related disorders can vary widely in their impact. Some newborns may have brief, self-resolving seizures with no lasting effects, while others experience more severe seizures that can interfere with their development. However, seizures are not always present—some children with KCNQ2-related disorders may primarily face developmental delays, movement difficulties, or other neurological challenges without ever experiencing seizures. The effects of a KCNQ2 genetic variation depend on the specific change in the gene, influencing the severity and symptoms a child may have.
Become a KCNQ2 champion. For every dollar you contribute, we are one step closer to a CURE.
The ABC's of KCNQ2
The KCNQ2 Cure Alliance (KCA) is dedicated to advancing research and resources for families affected by KCNQ2-related disorders, and its efforts have helped support greater awareness and understanding of these conditions. KCA has fostered research that informs families and medical professionals through advocacy, collaboration, and funding initiatives. KCNQ2- and KCNQ3-Associated Epilepsy, published in Cambridge Elements - Genetics in epilepsy, provides a comprehensive look at the role of KCNQ2 and KCNQ3 genes in neonatal-onset epilepsy, highlighting the variability of symptoms, from mild to severe, and the different ways these genetic mutations can affect development. This resource offers a clearer picture of what a KCNQ2-related diagnosis means, helping families navigate treatment options and better understand their child’s condition. The article serves as a critical reference for professionals, compiling the latest research on genetic mechanisms, clinical presentations, and emerging therapeutic approaches.
Subscribe to the KCNQ2 Connections Newsletter
For news and updates on the latest KCNQ2 research, clinical trials, conferences, and family meet-ups.
KCNQ2 Connections
KCNQ2-DEE Clinical Trial
Xenon Pharmaceuticals is currently developing XEN496, which is a proprietary pediatric formulation of the active ingredient ezogabine, for the treatment of KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE). Ezogabine was previously approved by the U.S. Food and Drug Administration (FDA), as an anti-epileptic drug as an adjunctive treatment for adults with focal seizures with or without…
Ode to a Cure
Our KCNQ2 Cure pal Dr. Phillip Pearl is on the front lines of the battle against COVID-19. Dr. Pearl is the Director of Epilepsy and Clinical Neurophysiology at Boston Children’s Hospital and a professor of neurology at Harvard University. He’s also a celebrated jazz musician. When I spoke to him recently, I asked him if…
KCNQ2 Cure's Fundraising Handbook
Be an active supporter in the quest to cure KCNQ2-Related Disorders. Download our toolkit to launch your personal fundraising event.
Our Partners
